WO2025093898 - COMPOSITION COMPRISING AVENANTHRAMIDE C FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CHONDROCYTES AND METHOD OF USING THE SAME
National phase entry:
Publication Number
WO/2025/093898
Publication Date
08.05.2025
International Application No.
PCT/IB2023/060888
International Filing Date
30.10.2023
Title **
[English]
COMPOSITION COMPRISING AVENANTHRAMIDE C FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CHONDROCYTES AND METHOD OF USING THE SAME
[French]
COMPOSITION COMPRENANT DE L'AVENANTHRAMIDE C POUR INDUIRE LA DIFFÉRENCIATION DE CELLULES SOUCHES MÉSENCHYMATEUSES EN CHONDROCYTES ET SON PROCÉDÉ D'UTILISATION
Applicants **
MEDEZE TREASURY PTE. LTD
Inventors
KHEMARANGSAN, Veerapol
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IPOS
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2296 | |
| EPO | Filing, Examination, Granting | 14741 | |
| Japan | Filing, Examination, Granting | 2371 | |
| South Korea | Filing, Examination, Granting | 2418 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
27,166
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention discloses an application of Avenanthramide C (Avn C) as an inducer of chondrocyte differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapies. By employing Avn C treatments, MSCs exhibit enhanced chondrocyte differentiation with elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably collagen type 2 (COL2A1). Moreover, a synergistic effect is observed when Avn C is used in combination with Chondroitin Sulfate (CS), resulting in the upregulation of the transcriptionally active state of SOX9, a crucial regulator of chondrogenesis. The disclosed invention demonstrates significant improvements in mRNA gene expressions (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).[French]
La présente invention concerne une application d'avenanthramide C (Avn C) en tant qu'inducteur de différenciation de chondrocytes dans des cellules souches mésenchymateuses (CSM), fournissant une approche prometteuse pour des thérapies cartilagineuses régénératives. En utilisant des traitements à l'Avn C, les CSM présentent une différenciation chondrocytaire accrue avec une expression élevée de facteurs clés spécifiques de la matrice extracellulaire chondrogénique (ECM), notamment le collagène de type 2 (COL2A1). De plus, un effet synergique est observé lorsque Avn C est utilisé en combinaison avec du sulfate de chondroïtine (CS), conduisant à la régulation à la hausse de l'état transcriptionnellement actif de SOX9, un régulateur crucial de la chondrogenèse. La présente invention démontre des améliorations significatives des expressions géniques d'ARNm (ACAN, LRP1, SOX9), des niveaux de protéines cellulaires (COL2A1, SOX9, LRP1), et des résultats fonctionnels, tels que mis en évidence par la sécrétion de protéines de matrice extracellulaire (FSTL-1, BGH3, CO1A1, CO1A2 et CO3A1).